Agios Pharmaceuticals (AGIO)

$31.46 +0.92 (3.01%)
Market Cap 1.79B
Revenue (ttm) 54.03M
Net Income (ttm) -412.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -763.98%
Debt to Equity Ratio 0.00
Volume 475,411
Avg Vol 1,175,428
Day's Range N/A - N/A
Shares Out 59.47M
Stochastic %K 14%
Beta 0.54
Analysts Strong Sell
Price Target $43.11

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pedi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 649 8600
Address:
88 Sidney Street, Cambridge, United States
stu4
stu4 Aug. 3 at 1:15 PM
$AGIO smart guy @lnoa !! Only misfits are here running the show ..no winners , no movers and shakers at the helm
0 · Reply
lnoa
lnoa Aug. 3 at 10:18 AM
$AGIO already out of this trashy !
0 · Reply
freddie04
freddie04 Jul. 30 at 2:14 PM
$AGIO Stated , well !!!
0 · Reply
freddie04
freddie04 Jul. 30 at 1:47 PM
$AGIO You must be so happy…join the other suckers , while mgmt sells their shares every chance they get ..w*ores
0 · Reply
freddie04
freddie04 Jul. 30 at 1:47 PM
$AGIO Proud ! .lol
0 · Reply
freddie04
freddie04 Jul. 30 at 1:45 PM
$AGIO Called the misfits at agios ..told ya
0 · Reply
EarningsInsider
EarningsInsider Jul. 30 at 1:16 PM
https://www.marketbeat.com/earnings/reports/2026-7-30-agios-pharmaceuticals-inc-stock/ $AGIO Agios Pharmaceuticals Earnings Transcript
0 · Reply
BiodegradableBurger
BiodegradableBurger Jul. 30 at 1:06 PM
$AGIO Brilliant ER and what the fcuk is this price action???
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 30 at 11:58 AM
$AGIO (+7.1% pre) AGIO: Q2 2026 revenue surged to $44.7M, with strong AQVESME launch and narrowed net loss https://ooc.bz/l/109188
0 · Reply
Merlintrader
Merlintrader Jul. 30 at 11:49 AM
$AGIO Breaking financial update · July 30, 2026 Mitapivat revenue more than doubles sequentially to $44.7M as the AQVESME launch gains traction https://www.merlintrader.com/agios-pharmaceuticals-stock-hub/
0 · Reply
Latest News on AGIO
Agios Pharmaceuticals price target raised to $52 from $46 at Citi

2026-07-31T10:16:19.000Z - 4 days ago

Agios Pharmaceuticals price target raised to $52 from $46 at Citi

Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright

2026-07-30T16:40:20.000Z - 5 days ago

Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright

Agios Pharmaceuticals Transcript: Transcript

Jul 30, 2026, 11:36 AM EDT - 5 days ago

Agios Pharmaceuticals Transcript: Transcript

Agios Pharmaceuticals Quarterly report

Jul 30, 2026, 9:57 AM EDT - 5 days ago

Agios Pharmaceuticals Quarterly report

Agios Pharmaceuticals Slides

Jul 30, 2026, 7:12 AM EDT - 5 days ago

Agios Pharmaceuticals Slides

Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)

2026-07-30T11:10:47.000Z - 5 days ago

Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)

Agios Pharmaceuticals Earnings release

Jul 30, 2026, 6:32 AM EDT - 5 days ago

Agios Pharmaceuticals Earnings release

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 30, 2026, 6:30 AM EDT - 5 days ago

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright

2026-07-21T15:05:37.000Z - 14 days ago

Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright

Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial

2026-07-21T12:20:27.000Z - 14 days ago

Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial

Agios Pharmaceuticals announces topline results from tebapivat trial

2026-07-21T11:21:10.000Z - 14 days ago

Agios Pharmaceuticals announces topline results from tebapivat trial

Agios Pharma to discontinue sickle cell disease treatment development

Jul 21, 2026, 7:07 AM EDT - 14 days ago

Agios Pharma to discontinue sickle cell disease treatment development

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Jul 21, 2026, 7:00 AM EDT - 14 days ago

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Agios Pharmaceuticals rises 13.5%

2026-07-07T16:05:37.000Z - 4 weeks ago

Agios Pharmaceuticals rises 13.5%

Leerink sees Priority Review designation as positive sign for Agios’ mitapivat

2026-07-07T15:40:11.000Z - 4 weeks ago

Leerink sees Priority Review designation as positive sign for Agios’ mitapivat

H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat

2026-07-07T15:25:11.000Z - 4 weeks ago

H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat

Agios Pharmaceuticals rises 12.9%

2026-07-07T14:06:03.000Z - 4 weeks ago

Agios Pharmaceuticals rises 12.9%

Agios Pharmaceuticals price target raised to $46 from $40 at BofA

2026-07-07T13:20:27.000Z - 4 weeks ago

Agios Pharmaceuticals price target raised to $46 from $40 at BofA

Agios Pharmaceuticals price target raised to $41 from $36 at Truist

2026-07-07T13:15:43.000Z - 4 weeks ago

Agios Pharmaceuticals price target raised to $41 from $36 at Truist

Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital

2026-07-07T11:31:01.000Z - 4 weeks ago

Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital

Agios Pharmaceuticals granted priority review for mitapivat sNDA

2026-07-07T11:16:10.000Z - 4 weeks ago

Agios Pharmaceuticals granted priority review for mitapivat sNDA

U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease

Jul 7, 2026, 7:00 AM EDT - 4 weeks ago

U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

Jun 29, 2026, 7:00 AM EDT - 5 weeks ago

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright

2026-06-15T10:06:50.000Z - 7 weeks ago

Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright

Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat

2026-06-14T20:35:05.000Z - 7 weeks ago

Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Jun 13, 2026, 9:00 AM EDT - 7 weeks ago

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Agios Pharmaceuticals Transcript: EHA 2026

Jun 13, 2026, 9:00 AM EDT - 7 weeks ago

Agios Pharmaceuticals Transcript: EHA 2026

Agios Pharmaceuticals Slides: FY 2026

Jun 13, 2026, 9:00 AM EDT - 7 weeks ago

Agios Pharmaceuticals Slides: FY 2026

Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan

2026-06-10T23:45:10.000Z - 7 weeks ago

Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan

Agios Pharmaceuticals Transcript: Status update

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Agios Pharmaceuticals Transcript: Status update

Agios Pharmaceuticals Slides: Status update

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Agios Pharmaceuticals Slides: Status update

Agios Pharmaceuticals Press release: Status update

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Agios Pharmaceuticals Press release: Status update

Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib

2026-06-01T09:13:35.000Z - 2 months ago

Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Jun 1, 2026, 5:00 AM EDT - 2 months ago

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Agios Pharmaceuticals price target lowered to $40 from $41 at BofA

2026-05-29T15:28:43.000Z - 2 months ago

Agios Pharmaceuticals price target lowered to $40 from $41 at BofA

Agios scraps blood cancer drug program after study miss

May 29, 2026, 7:21 AM EDT - 2 months ago

Agios scraps blood cancer drug program after study miss

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

May 29, 2026, 7:00 AM EDT - 2 months ago

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

May 22, 2026, 10:18 AM EDT - 2 months ago

Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

May 22, 2026, 9:15 AM EDT - 2 months ago

Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

Agios Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 11:00 AM EDT - 2 months ago

Agios Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

May 12, 2026, 9:31 AM EDT - 3 months ago

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

May 12, 2026, 9:30 AM EDT - 3 months ago

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Agios Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Agios Pharmaceuticals Earnings Call Transcript: Q1 2026

Agios Pharmaceuticals Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Agios Pharmaceuticals Earnings release: Q1 2026

Agios Pharmaceuticals Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Agios Pharmaceuticals Slides: Q1 2026

Agios Pharmaceuticals Quarterly report: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Agios Pharmaceuticals Quarterly report: Q1 2026

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 29, 2026, 6:30 AM EDT - 3 months ago

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Agios Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Agios Pharmaceuticals Proxy statement: Proxy filing

Agios Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Agios Pharmaceuticals Proxy statement: Proxy filing

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Apr 6, 2026, 7:00 AM EDT - 4 months ago

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

Mar 31, 2026, 8:45 AM EDT - 4 months ago

PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Mar 31, 2026, 7:00 AM EDT - 4 months ago

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Agios Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:50 AM EST - 5 months ago

Agios Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

Mar 2, 2026, 7:00 AM EST - 5 months ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

Agios Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:00 AM EST - 6 months ago

Agios Pharmaceuticals Earnings Call Transcript: Q4 2025

Agios Pharmaceuticals Annual report: Q4 2025

Feb 12, 2026, 8:00 AM EST - 6 months ago

Agios Pharmaceuticals Annual report: Q4 2025

Agios Pharmaceuticals Earnings release: Q4 2025

Feb 12, 2026, 8:00 AM EST - 6 months ago

Agios Pharmaceuticals Earnings release: Q4 2025

Agios Pharmaceuticals Slides: Q4 2025

Feb 12, 2026, 8:00 AM EST - 6 months ago

Agios Pharmaceuticals Slides: Q4 2025

Agios Pharmaceuticals Annual report: Q4 2025

Feb 12, 2026, 8:00 AM EST - 6 months ago

Agios Pharmaceuticals Annual report: Q4 2025

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 12, 2026, 6:30 AM EST - 6 months ago

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Jan 26, 2026, 7:00 AM EST - 6 months ago

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Agios Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 11:15 AM EST - 7 months ago

Agios Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Agios Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 11:15 AM EST - 7 months ago

Agios Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Jan 12, 2026, 7:00 AM EST - 7 months ago

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Jan 5, 2026, 7:00 AM EST - 7 months ago

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Dec 24, 2025, 9:56 AM EST - 7 months ago

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

Dec 24, 2025, 8:22 AM EST - 7 months ago

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

Agios Pharmaceuticals Transcript: FDA Announcement

Dec 24, 2025, 8:00 AM EST - 7 months ago

Agios Pharmaceuticals Transcript: FDA Announcement

Agios Pharmaceuticals Press release: FDA Announcement

Dec 24, 2025, 8:00 AM EST - 7 months ago

Agios Pharmaceuticals Press release: FDA Announcement

Agios Pharmaceuticals Slides: FDA Announcement

Dec 24, 2025, 8:00 AM EST - 7 months ago

Agios Pharmaceuticals Slides: FDA Announcement

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Dec 23, 2025, 7:45 PM EST - 7 months ago

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Dec 8, 2025, 7:00 AM EST - 8 months ago

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Nov 19, 2025, 8:24 AM EST - 9 months ago

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Agios Pharmaceuticals Transcript: Study Result

Nov 19, 2025, 8:00 AM EST - 9 months ago

Agios Pharmaceuticals Transcript: Study Result

Agios Pharmaceuticals Press release: Study Result

Nov 19, 2025, 8:00 AM EST - 9 months ago

Agios Pharmaceuticals Press release: Study Result

Agios Pharmaceuticals Slides: Study Result

Nov 19, 2025, 8:00 AM EST - 9 months ago

Agios Pharmaceuticals Slides: Study Result

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Nov 19, 2025, 7:00 AM EST - 9 months ago

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:01 AM EST - 9 months ago

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Agios Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Agios Pharmaceuticals Earnings Call Transcript: Q3 2025

Agios Pharmaceuticals Quarterly report: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Agios Pharmaceuticals Quarterly report: Q3 2025

Agios Pharmaceuticals Earnings release: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Agios Pharmaceuticals Earnings release: Q3 2025

Agios Pharmaceuticals Slides: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Agios Pharmaceuticals Slides: Q3 2025

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 6:30 AM EDT - 9 months ago

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Oct 17, 2025, 8:15 AM EDT - 10 months ago

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Oct 17, 2025, 8:00 AM EDT - 10 months ago

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

Oct 16, 2025, 7:00 AM EDT - 10 months ago

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Sep 4, 2025, 7:00 AM EDT - 11 months ago

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Aug 4, 2025, 4:01 PM EDT - 1 year ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios Pharmaceuticals Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Agios Pharmaceuticals Earnings Call Transcript: Q2 2025

Agios Pharmaceuticals Quarterly report: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Agios Pharmaceuticals Quarterly report: Q2 2025

Agios Pharmaceuticals Earnings release: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Agios Pharmaceuticals Earnings release: Q2 2025

Agios Pharmaceuticals Slides: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Agios Pharmaceuticals Slides: Q2 2025

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 6:30 AM EDT - 1 year ago

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Jul 14, 2025, 7:00 AM EDT - 1 year ago

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Agios Appoints Dr. Jay Backstrom to Board of Directors

Jul 8, 2025, 7:00 AM EDT - 1 year ago

Agios Appoints Dr. Jay Backstrom to Board of Directors

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Jun 9, 2025, 8:40 AM EDT - 1 year ago

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Agios Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 8:40 AM EDT - 1 year ago

Agios Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

May 28, 2025, 7:00 AM EDT - 1 year ago

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

Agios Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 21, 2025, 8:00 AM EDT - 1 year ago

Agios Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2025

Agios Pharmaceuticals Transcript: Bank of America 2025 Healthcare Conference

May 14, 2025, 11:00 AM EDT - 1 year ago

Agios Pharmaceuticals Transcript: Bank of America 2025 Healthcare Conference

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

May 14, 2025, 10:00 AM EDT - 1 year ago

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

stu4
stu4 Aug. 3 at 1:15 PM
$AGIO smart guy @lnoa !! Only misfits are here running the show ..no winners , no movers and shakers at the helm
0 · Reply
lnoa
lnoa Aug. 3 at 10:18 AM
$AGIO already out of this trashy !
0 · Reply
freddie04
freddie04 Jul. 30 at 2:14 PM
$AGIO Stated , well !!!
0 · Reply
freddie04
freddie04 Jul. 30 at 1:47 PM
$AGIO You must be so happy…join the other suckers , while mgmt sells their shares every chance they get ..w*ores
0 · Reply
freddie04
freddie04 Jul. 30 at 1:47 PM
$AGIO Proud ! .lol
0 · Reply
freddie04
freddie04 Jul. 30 at 1:45 PM
$AGIO Called the misfits at agios ..told ya
0 · Reply
EarningsInsider
EarningsInsider Jul. 30 at 1:16 PM
https://www.marketbeat.com/earnings/reports/2026-7-30-agios-pharmaceuticals-inc-stock/ $AGIO Agios Pharmaceuticals Earnings Transcript
0 · Reply
BiodegradableBurger
BiodegradableBurger Jul. 30 at 1:06 PM
$AGIO Brilliant ER and what the fcuk is this price action???
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 30 at 11:58 AM
$AGIO (+7.1% pre) AGIO: Q2 2026 revenue surged to $44.7M, with strong AQVESME launch and narrowed net loss https://ooc.bz/l/109188
0 · Reply
Merlintrader
Merlintrader Jul. 30 at 11:49 AM
$AGIO Breaking financial update · July 30, 2026 Mitapivat revenue more than doubles sequentially to $44.7M as the AQVESME launch gains traction https://www.merlintrader.com/agios-pharmaceuticals-stock-hub/
0 · Reply
freddie04
freddie04 Jul. 30 at 11:17 AM
$AGIO as thought, can’t find it , hahahaha
0 · Reply
freddie04
freddie04 Jul. 30 at 11:13 AM
$AGIO Show the post of Leerink Partners LLC , hahaha. @IN0V8 …Robby , lol ..or is this another sham !
0 · Reply
freddie04
freddie04 Jul. 30 at 11:10 AM
$AGIO Leerink has been wrong on this stock since 2022 Butt boy Behrens at leerink is a total buffoon
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 30 at 10:37 AM
$AGIO Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.69 up 12.44% YoY • Reported revenue of $44.74M up 259.25% YoY
0 · Reply
Merlintrader
Merlintrader Jul. 29 at 6:19 PM
$AGIO Agios Pharmaceuticals ($AGIO) Stock Hub 2026: From Mitapivat Launch Story To Broader Rare-Disease Hematology Platform https://www.merlintrader.com/agios-pharmaceuticals-stock-hub/
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Jul. 29 at 9:41 AM
$AGIO bought 1000 shares yesterday.
0 · Reply
IN0V8
IN0V8 Jul. 28 at 2:58 PM
$AGIO Buy Leerink Partners raises PT to $62 from $59
0 · Reply
stu4
stu4 Jul. 23 at 1:21 AM
$AGIO as stated for years …misfits exist at Agios
0 · Reply
flychicken1991
flychicken1991 Jul. 21 at 4:13 PM
$AGIO Negative (91%): shares face downward pressure because terminating the sickle cell program eliminates a potential commercial indication and forces investors to reduce the probability-adjusted value assigned to tebapivat. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/9767b12ef68c9ef3?utm_source=stocktwits&utm_medium=story_url
0 · Reply
stu4
stu4 Jul. 21 at 3:35 PM
$AGIO Wainwright says $52….in 2022 ..they said July 2022 $95 !!! Hahahahaa …..MIKE KING was the author Now pumping GAS on 97th west broadway and park , NY, NY
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 21 at 2:09 PM
Why Is AGIO Stock Falling Today? $AGIO https://stocktwits.com/news/equity/markets/why-is-agio-stock-falling-today/cZZSfDCR7va
0 · Reply
stu4
stu4 Jul. 21 at 1:10 PM
$AGIO And the saga continues of incompetence. Now you know why Bellevenue , an insider for 6 years sold out Nov 15 2025 for a loss of 40M on their LONG TERM HOLD . FOUSE FCUKED Them hard , they will never forget, and will SHORT this as long as she exits as their Chairman of the Board ! Today is another wake up call for this welfare office for senior misfit biotech reject personnel . BALANT incompetence. Not a renown scientist exists in the company any longer !!!
0 · Reply